| 0 (0%) | 06-28 18:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.87 | 1-year : | 13.78 |
| Resists | First : | 11.02 | Second : | 11.8 |
| Pivot price | 11.02 |
|||
| Supports | First : | 9.76 | Second : | 8.12 |
| MAs | MA(5) : | 10.51  |
MA(20) : | 10.86 |
| MA(100) : | 10.72 |
MA(250) : | 10.38 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 17.7 |
D(3) : | 19.2 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 13.23 | Low : | 8.06 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ROIV ] has closed above bottom band by 25.9%. Bollinger Bands are 4.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.83 - 10.89 | 10.89 - 10.93 |
| Low: | 10.23 - 10.29 | 10.29 - 10.35 |
| Close: | 10.5 - 10.6 | 10.6 - 10.69 |
Mon, 22 Apr 2024
Spanish drugmaker Rovi to make ingredients for Moderna COVID-19 vaccine - Yahoo Movies Canada
Sat, 20 Apr 2024
Rovi loses patent fight with Amazon in U.S. appeals court - Yahoo Movies Canada
Wed, 17 Apr 2024
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well - Simply Wall St
Thu, 14 Mar 2024
Laboratorios Rovi, Insud Pharma and Ministry of Science form partnership to research advanced therapies | The Corner - The Corner Economic
Thu, 07 Mar 2024
Rovi explores sale of unit that makes drugs for third parties - AOL
Wed, 28 Feb 2024
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 806 (M) |
| Held by Insiders | 4.2163e+008 (%) |
| Held by Institutions | 20.6 (%) |
| Shares Short | 27,690 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.03e+009 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 3 % |
| Operating Margin | 624.1 % |
| Return on Assets (ttm) | -774.2 % |
| Return on Equity (ttm) | -13.8 % |
| Qtrly Rev. Growth | 1.2324e+008 % |
| Gross Profit (p.s.) | 87.91 |
| Sales Per Share | 78.95 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 5.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -836 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.13 |
| Price to Cash Flow | 1.87 |
| Dividend | 0 |
| Forward Dividend | 3.093e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|